Literature DB >> 16688795

Extremely well-differentiated adenocarcinoma of the stomach: clinicopathological and immunohistochemical features.

Takashi Yao1, Takashi Utsunomiya, Masafumi Oya, Kenichi Nishiyama, Masazumi Tsuneyoshi.   

Abstract

AIM: Minimal deviation carcinoma of the uterine cervix, otherwise known as extremely well-differentiated adenocarcinoma (EWDA), is characterized by its benign microscopic appearance in contrast to its aggressive behavior. In order to elucidate the clinicopathological features and biological behavior of the gastric counterpart of EWDA, we, using immunohistochemistry, analyzed nine lesions for the phenotypic expression, proliferative activity, and the expression of oncogene-associated products.
METHODS: Clinicopathological features, including pre-operative biopsy diagnosis, were reviewed. Using immunohistochemistry, Ki-67 labeling index and expression of p53 and c-erbB-2 protein in the gastric lesions were detected. RESULT: Locations in the middle or upper third of the stomach and polypoid macroscopic features are characteristic of EWDA of the stomach. Although 4 of the 9 lesions showed only focal lymphatic or venous invasion, lymph node metastasis was not present and none of the patients died of the lesions (mean follow-up period, 56 mo). All 9 cases of EWDA could be classified into gastric phenotype (5 lesions) and intestinal phenotype (4 lesions). The former resembled gastric foveolar epithelium, mucous neck cells or pyloric glands, but their papillary structures were frequently elongated and the tumor cells and their nuclei were slightly larger and more hyperchromatic compared to normal epithelium. The latter resembled intestinal metaplasia with minimal nuclear atypia and irregular glands; two of these lesions demonstrated complete intestinal phenotype, while two demonstrated incomplete intestinal phenotype. Ki-67 labeling index was low and none of the cases revealed over-expression of p53 and c-erbB-2 protein.
CONCLUSION: Unlike minimal deviation carcinoma of the cervix, these findings suggest that EWDA of the stomach is a lesion of low-grade malignancy. This favorable biological behavior is supported by the data of a low Ki-67 labeling index and a lack of p53 or c-erbB-2 protein over-expression. Because of its resemblance to normal gastric mucosa or mucosa with intestinal metaplasia, EWDA is often misdiagnosed. To prevent the misdiagnosis of such lesions, the clinical and pathologic characteristics should be taken into consideration.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16688795      PMCID: PMC4087982          DOI: 10.3748/wjg.v12.i16.2510

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  34 in total

1.  MUC gene expression and histogenesis of adenocarcinoma of the stomach.

Authors:  S Tsukashita; R Kushima; M Bamba; H Sugihara; T Hattori
Journal:  Int J Cancer       Date:  2001-10-15       Impact factor: 7.396

2.  Oncofetal mucin M1 epitope family: characterization and expression during colonic carcinogenesis.

Authors:  J Bara; R Gautier; P Mouradian; C Decaens; N Daher
Journal:  Int J Cancer       Date:  1991-01-21       Impact factor: 7.396

3.  Relationship between biologic behavior and phenotypic expression in intramucosal gastric carcinomas.

Authors:  Akira Kabashima; Takashi Yao; Keizo Sugimachi; Masazumi Tsuneyoshi
Journal:  Hum Pathol       Date:  2002-01       Impact factor: 3.466

4.  Predictive value of cathepsin D and Ki-67 expression at the deepest penetration site for lymph node metastases in gastric cancer.

Authors:  H Goishi; S Tanaka; K Haruma; M Yoshihara; K Sumii; G Kajiyama; F Shimamoto
Journal:  Oncol Rep       Date:  2000 Jul-Aug       Impact factor: 3.906

5.  Gastric or intestinal phenotypic expression in the carcinomas and background mucosa of multiple early gastric carcinomas.

Authors:  A Kabashima; T Yao; K Sugimachi; M Tsuneyoshi
Journal:  Histopathology       Date:  2000-12       Impact factor: 5.087

6.  Human gastric mucin. Identification of a unique species by expression cloning.

Authors:  N W Toribara; A M Roberton; S B Ho; W L Kuo; E Gum; J W Hicks; J R Gum; J C Byrd; B Siddiki; Y S Kim
Journal:  J Biol Chem       Date:  1993-03-15       Impact factor: 5.157

7.  [Mucin histochemical study of differentiated adenocarcinoma of stomach].

Authors:  Y Egashira
Journal:  Nihon Shokakibyo Gakkai Zasshi       Date:  1994-04

8.  Heterogeneity of mucin gene expression in normal and neoplastic tissues.

Authors:  S B Ho; G A Niehans; C Lyftogt; P S Yan; D L Cherwitz; E T Gum; R Dahiya; Y S Kim
Journal:  Cancer Res       Date:  1993-02-01       Impact factor: 12.701

9.  Cell proliferation, apoptosis and angiogenesis in gastric cancer and its hepatic metastases.

Authors:  Naohiko Koide; Akihito Nishio; Manabu Hiraguri; Ko Shimada; Nobuhiko Shimozawa; Kazuhiro Hanazaki; Shoji Kajikawa; Wataru Adachi; Jun Amano
Journal:  Hepatogastroenterology       Date:  2002 May-Jun

10.  Distribution of common acute lymphoblastic leukemia antigen in nonhematopoietic tissues.

Authors:  R S Metzgar; M J Borowitz; N H Jones; B L Dowell
Journal:  J Exp Med       Date:  1981-10-01       Impact factor: 14.307

View more
  15 in total

1.  Histotype-based prognostic classification of gastric cancer.

Authors:  Anna Maria Chiaravalli; Catherine Klersy; Alessandro Vanoli; Andrea Ferretti; Carlo Capella; Enrico Solcia
Journal:  World J Gastroenterol       Date:  2012-03-07       Impact factor: 5.742

2.  Mucin phenotype of gastric cancer and clinicopathology of gastric-type differentiated adenocarcinoma.

Authors:  Tsutomu Namikawa; Kazuhiro Hanazaki
Journal:  World J Gastroenterol       Date:  2010-10-07       Impact factor: 5.742

3.  Gastric adenocarcinoma of fundic gland type: Five cases treated with endoscopic resection.

Authors:  Masaki Miyazawa; Mitsuru Matsuda; Masaaki Yano; Yasumasa Hara; Fumitaka Arihara; Yosuke Horita; Koichiro Matsuda; Akito Sakai; Yatsugi Noda
Journal:  World J Gastroenterol       Date:  2015-07-14       Impact factor: 5.742

4.  Distinct expression profile of key molecules in crawling-type early gastric carcinoma.

Authors:  Ha Young Woo; Yoon Sung Bae; Jie-Hyun Kim; Sang Kil Lee; Yong Chan Lee; Jae-Ho Cheong; Sung Hoon Noh; Hyunki Kim
Journal:  Gastric Cancer       Date:  2016-10-12       Impact factor: 7.370

5.  Incidence of lymphatic involvement in differentiated-type intramucosal gastric cancers as examined by endoscopic resection.

Authors:  Yasuko Fujita; Mitsuo Kishimoto; Ryuta Nakao; Reiko Kimura-Tsuchiya; Nobuaki Yagi; Akio Yanagisawa
Journal:  Gastric Cancer       Date:  2015-02-01       Impact factor: 7.370

6.  Extremely Well-Differentiated Gastric Adenocarcinoma Arising in Pylorus with Minor Diffuse Adenocarcinoma Component.

Authors:  Zoran Jukić; Jasna Bacalja; Jozo Kristek; Miroslav Bekavac-Bešlin; Božo Krušlin
Journal:  J Gastrointest Cancer       Date:  2018-03

7.  Differentiated adenocarcinoma with a gastric phenotype in the stomach: difficulties in clinical and pathological diagnoses.

Authors:  Tsutomu Namikawa; Michiya Kobayashi; Hiroyuki Kitagawa; Takehiro Okabayashi; Takeki Sugimoto; Yoshinori Kuratani; Manabu Matsumoto; Kazuhiro Hanazaki
Journal:  Clin J Gastroenterol       Date:  2009-05-29

8.  Gastric-Type Extremely Well-Differentiated Adenocarcinoma of the Stomach: A Challenge for Preoperative Diagnosis.

Authors:  Mee Joo; Song Hee Han
Journal:  J Pathol Transl Med       Date:  2015-09-30

Review 9.  Gastric adenocarcinoma of the fundic gland (chief cell-predominant type): A review of endoscopic and clinicopathological features.

Authors:  Masaki Miyazawa; Mitsuru Matsuda; Masaaki Yano; Yasumasa Hara; Fumitaka Arihara; Yosuke Horita; Koichiro Matsuda; Akito Sakai; Yatsugi Noda
Journal:  World J Gastroenterol       Date:  2016-12-28       Impact factor: 5.742

10.  Initiation of inflammatory tumorigenesis by CTLA4 insufficiency due to type 2 cytokines.

Authors:  Jason Miska; Jen Bon Lui; Kevin H Toomer; Priyadharshini Devarajan; Xiaodong Cai; JeanMarie Houghton; Diana M Lopez; Maria T Abreu; Gaofeng Wang; Zhibin Chen
Journal:  J Exp Med       Date:  2018-01-26       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.